ERVW-1 and myeloid sarcoma: In addition, the same peptides employed in the current study, HERV-W-env(93–108) and HERV-W-env(248–262), showed significant immunoreactivity with recognition rates of 31.25% (p < 0.0001) in MS patients and 15% (p = 0.02) in the HCs group [4].